Blinatumomab
Blinatumomab (pronounced as blih-NOO-toh-MOH-bab) is a type of biopharmaceutical used in the treatment of certain types of cancer, specifically acute lymphoblastic leukemia (ALL).
Etymology
The name "Blinatumomab" is derived from its nature as a bispecific T-cell engager (BiTE), with "blin" referring to "bispecific lymphocyte engager" and "mab" standing for "monoclonal antibody".
Usage
Blinatumomab is used to treat B-cell precursor ALL, a type of blood and bone marrow cancer. It is used when the cancer has come back or has not gone away after treatment (refractory). It is a type of monoclonal antibody and a type of bispecific T cell engager.
Mechanism of Action
Blinatumomab works by linking B cells and T cells together, which allows the T cells to attack and kill the cancerous B cells. This is achieved through the dual affinity of the drug, which binds to both CD19 on the B cells and CD3 on the T cells.
Related Terms
- Monoclonal Antibody
- Bispecific T-cell Engager
- Acute Lymphoblastic Leukemia
- Biopharmaceutical
- CD19
- CD3
See Also
External links
- Medical encyclopedia article on Blinatumomab
- Wikipedia's article - Blinatumomab
This WikiMD article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski